MetalloBio's mission is fundamentally to change the nature of antibiotics and the treatment of infections.
Dr Michael Murray, CEO of MetalloBio, will be contributing to the panel “Why my technology would appear cheap at twice the price?” This discussion will explore the vexed issue of asset valuation in deals between innovator companies and major multinationals.